Angtuo
昂拓生物
Angtuo (昂拓生物, Arnatar / Arnatar Therapeutics) is a nucleic-acid drug developer founded in 2022 by a team of top global scientists in the field . The company focuses on novel antisense nucleic acid technology and RNA-targeted drug R&D, and has built a proprietary dual-modality platform called DARGER™ . In April 2024 it raised over $50 million in a Series A round led by Eight Roads, Bencao Capital, Huajin Capital, Gaorong Ventures and Jifeng Capital, with proceeds earmarked for pipeline expansion and clinical-trial acceleration . By late 2025 its ASO candidate ART4 had received both FDA orphan-drug and rare-pediatric-disease designations .
AI-generated — may contain errors, please verify.
Coverage
Small Nucleic Acid Drugs Enter a New Era, Onto Bio: Pioneering Antisense Upregulation Technology Opens a New Chapter in Cures | Gaorong Future
Moving from "symptomatic treatment" to "disease-modifying therapy."
高榕创投·Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
高榕创投·Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
高榕创投·Onto Innovation Completes Over $50 Million Series A Financing to Accelerate Deep Pipeline Expansion in Nucleic Acid Drugs
Focused on drug development based on antisense oligonucleotide technology.
高榕创投·
